CRISPR Therapeutics AG Common Shares (CRSP)
CRSP trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/0001193125-26-048957-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CRSP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Switzerland |
| IPO year | 2016 |
| SEC CIK | 0001674416 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Switzerland |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.5M |
| Net income | -$581.6M |
| Operating income | -$664.6M |
| Net margin | -16569.8% |
| Operating margin | -18933.6% |
| Revenue growth | -90.6% |
| Cash | $347.6M |
| Total assets | $2.3B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1115.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-02 |
| Cash and burn | $192.0M cash; operating cash flow -$93.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 97,000,813 (2026-10-30); 95,300,233 a year earlier; 79,432,446 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-04 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $18.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $12.7M | -$111.4M | -$89.7M | $192.0M | $586.9M | $25.2M | 10-Q 2026-11-02 |
| Q2 2026 2026-06-30 | $10.2M | -$91.2M | -$83.5M | $291.3M | $586.2M | $13.4M | 10-Q 2026-08-03 |
| Q1 2026 2026-03-31 | $1.5M | -$122.9M | -$108.9M | $423.3M | $585.5M | $4.1M | 10-Q 2026-05-04 |
| Q4 2025 2025-12-31 | $864K | -$130.6M | -$92.6M | $347.6M | $0 | $3.5M | 10-K 2026-02-12 |
| Q3 2025 2025-09-30 | $889K | -$106.4M | -$84.6M | $286.5M | No debt tags | $38.3M | 10-Q 2026-11-02 |
| Q2 2025 2025-06-30 | $892K | -$208.5M | -$113.9M | $193.6M | No debt tags | $38.0M | 10-Q 2026-08-03 |
| Q1 2025 2025-03-31 | $865K | -$136.0M | -$53.9M | $235.2M | No debt tags | $37.7M | 10-Q 2026-05-04 |
| Q4 2024 2024-12-31 | $35.7M | -$37.3M | -$50.0M | $298.3M | No debt tags | $37.3M | 10-K 2026-02-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-10-15 |
| Latest annual report | 10-K | 2026-02-12 |
| Latest quarterly / interim | 10-Q | 2026-11-02 |
| Latest current report | 8-K | 2026-11-02 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 885 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -15.6% |
| 1 month | -15.7% |
| 3 months | -21.8% |
| Year to date | -19.5% |
| 1 year | -17.4% |
| From 52-week high | -31.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TARS | Tarsus Pharmaceuticals Inc. | $78.68 | -1.99% | $3.9B |
| RLAY | Relay Therapeutics Inc. | $17.27 | -4.53% | $3.8B |
| IOVA | Iovance Biotherapeutics Inc. | $7.55 | -2.71% | $3.5B |
| ADPT | Adaptive Biotechnologies Corporation | $27.87 | -4.03% | $4.5B |
| ADMA | ADMA Biologics Inc | $13.47 | -1.54% | $3.0B |
| VCEL | Vericel Corporation | $57.48 | +0.91% | $2.9B |
| DNLI | Denali Therapeutics Inc. | $18.08 | -3.52% | $2.9B |
| SRRK | Scholar Rock Holding Corporation | $44.54 | +3.09% | $5.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier